We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Compound Prevents Breast Cancer in Mice

By Biotechdaily staff writers
Posted on 08 Nov 2004
A new compound developed through the combined use of chemistry, biology, bioinformatics, pharmacology, and mathematics has been shown capable of preventing breast cancer in mice.

The compound was developed by researchers at Parker Hughes (Roseville, MN, USA). Called Compound 003, the compound prolonged cancer-free survival in transgenic mice that otherwise invariably develop HER2-positive metastatic breast cancer. The compound is a novel cytotoxic nucleoside analog and was well tolerated in both mice and rats without toxicity.

The research results were published in the November 2004 issue of the international medical journal Arzneimittelforschung. Women with HER2-positive breast cancer have a greater risk for recurrence of their breast cancer and an increased risk of mortality. Roughly 40,000 women in the United States alone die each year from breast cancer.




Related Links:
Parker Hughes

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Automated Urinalysis Solution
UN-9000
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group

Latest BioResearch News

Study Identifies Protein Changes Driving Immunotherapy Resistance in Multiple Myeloma
08 Nov 2004  |   BioResearch

Genetic Analysis Identifies BRCA-Linked Risks Across Multiple Cancers
08 Nov 2004  |   BioResearch

Study Identifies Hidden B-Cell Mutations in Autoimmune Disease
08 Nov 2004  |   BioResearch